

# Johnson & Johnson Innovative Medicine's approach to pre-approval access

At Johnson & Johnson (J&J) Innovative Medicine, our **Credo** guides our decision-making. We are driven to find solutions to some of the most complex medical challenges. The following highlights our approach to evaluating requests for medicines not yet approved by health authorities.



## What

is pre-approval access?



Pre-approval access (PAA), also known as expanded access or compassionate use, **is a way for eligible patients to access investigational medicines that have not yet been approved** by health authorities.



## Why

does J&J Innovative Medicine Support PAA?




J&J Innovative Medicine provides pathways for patients with serious health conditions to gain access to investigational treatments, **advancing patient care and public health**, which is our first priority.



## Who

is eligible for PAA?

Patients may be eligible for PAA if they:



## When

will a decision about a PAA request from J&J Innovative Medicine be available?

We commit to providing a decision as quickly as possible, ideally, within **5 to 10 business days** of receiving all required medical information.



## How

does a physician submit a PAA request to J&J Innovative Medicine?

In the US:  
1-800-JANSSEN  
OR  
[janssenmedinfo@its.jnj.com](mailto:janssenmedinfo@its.jnj.com)



Outside the US:  
<http://www.janssen.com/contact-us>



## Where

can additional information on PAA be found?



<http://www.janssen.com/compassionate-use-pre-approval-access>